Ulevostinag

DRUG2 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

Head and Neck Squamous Cell Carcinoma (HNSCC)LymphomaSolid Tumors

Phase 1

Study of Ulevostinag (MK-1454) Alone or in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors or Lymphomas (MK-1454-001)

CompletedNCT03010176

Merck Sharp & Dohme LLCLymphoma, Solid Tumors

Start: 2017-02-03End: 2022-04-21Updated: 2025-10-29

Phase 2

Study of Intratumoral (IT) Ulevostinag (MK-1454) in Combination With Intravenous (IV) Pembrolizumab (MK-3475) Compared to IV Pembrolizumab Alone as the First Line Treatment of Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) (MK-1454-002)

CompletedNCT04220866

Merck Sharp & Dohme LLCHead and Neck Squamous Cell Carcinoma (HNSCC)

Start: 2020-03-04End: 2022-09-30Updated: 2025-10-29

Related Papers

Phase I and II Clinical Studies of the STING Agonist Ulevostinag with and without Pembrolizumab in Participants with Advanced or Metastatic Solid Tumors or Lymphomas

Clinical Cancer Research2025-06-1117 citations

CASTING: A Potent Supramolecular Strategy to Cytosolically Deliver STING Agonist for Cancer Immunotherapy and SARS-CoV-2 Vaccination

CCS Chemistry2022-05-1752 citations

A kinase-cGAS cascade to synthesize a therapeutic STING activator.

2022-03-1676 citations

The Age of Cyclic Dinucleotide Vaccine Adjuvants.

2020-08-1374 citations